FibroBiologics, Inc.
FBLG
$0.35
$0.025.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.21% | 22.30% | 31.44% | 41.60% | 48.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.10% | 43.54% | 47.09% | 54.53% | 62.12% |
| Operating Income | -42.10% | -43.54% | -47.09% | -54.53% | -62.12% |
| Income Before Tax | -4.06% | 32.09% | 65.97% | 32.30% | -114.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.06% | 32.09% | 65.97% | 32.30% | -114.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.06% | 32.09% | 65.97% | 32.30% | -114.41% |
| EBIT | -42.10% | -43.54% | -47.09% | -54.53% | -62.12% |
| EBITDA | -41.90% | -43.26% | -46.53% | -53.58% | -93.38% |
| EPS Basic | 20.30% | 45.71% | 72.25% | 48.16% | -56.77% |
| Normalized Basic EPS | 20.27% | 45.69% | 72.26% | 40.08% | -105.34% |
| EPS Diluted | 20.30% | 45.71% | 72.25% | 48.16% | -56.77% |
| Normalized Diluted EPS | 20.27% | 45.69% | 72.26% | 40.08% | -105.34% |
| Average Basic Shares Outstanding | 21.42% | 18.82% | 18.31% | 16.45% | 11.23% |
| Average Diluted Shares Outstanding | 21.42% | 18.82% | 18.31% | 16.45% | 11.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |